Repligen logged a 7.6% change during today's morning session, and is now trading at a price of $162.17 per share.
Repligen returned losses of -22.1% last year, with its stock price reaching a high of $203.13 and a low of $113.5. Over the same period, the stock underperformed the S&P 500 index by -42.8%. AThe company's 50-day average price was $155.05. Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. Based in Waltham, MA, the Mid-Cap Health Care company has 1,783 full time employees. Repligen has not offered a dividend during the last year.
Increasing Revenues but Narrowing Margins:
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Revenue (k) | $194,032 | $270,245 | $366,260 | $670,534 | $801,536 | $638,764 |
| Operating Margins | 13% | 13% | 19% | 25% | 28% | 9% |
| Net Margins | 9% | 8% | 16% | 19% | 23% | 7% |
| Net Income (k) | $16,617 | $21,411 | $59,926 | $128,291 | $185,959 | $41,577 |
| Net Interest Expense (k) | $6,709 | $9,292 | $10,768 | $11,278 | $1,162 | $1,951 |
| Depreciation & Amort. (k) | $15,778 | $20,868 | $27,067 | $38,447 | $50,985 | $68,085 |
| Diluted Shares (k) | 45,471 | 49,206 | 53,892 | 57,264 | 57,455 | 56,377 |
| Earnings Per Share | $0.37 | $0.44 | $1.11 | $2.24 | $3.24 | $0.74 |
| EPS Growth | n/a | 18.92% | 152.27% | 101.8% | 44.64% | -77.16% |
| Avg. Price | $46.7 | $74.51 | $135.14 | $231.7 | $173.93 | n/a |
| P/E Ratio | 122.89 | 169.34 | 118.54 | 99.44 | 51.92 | nan |
| Free Cash Flow (k) | $22,135 | $48,712 | $40,170 | $51,927 | $87,249 | $77,696 |
| CAPEX (k) | $10,635 | $18,504 | $22,455 | $67,089 | $84,834 | $36,222 |
| EV / EBITDA | 46.57 | 52.27 | 67.76 | 60.0 | 34.04 | nan |
| Total Debt (k) | $103,488 | $232,767 | $243,737 | $255,258 | $284,615 | $579,595 |
| Net Debt / EBITDA | -2.16 | -5.19 | -4.89 | -1.69 | -0.87 | -1.4 |
| Current Ratio | 2.12 | 13.28 | 2.83 | 2.48 | 2.47 | 7.02 |
Repligen benefits from rapidly growing revenues and increasing reinvestment in the business, an excellent current ratio of 7.02, and a strong EPS growth trend. The company's financial statements show positive cash flows and healthy leverage levels. However, the firm has weak operating margins with a negative growth trend.
Repligen does not have a meaningful trailing P/E ratio since its earnings per share are currently in the red. Based on its EPS guidance of $1.78, the company has a forward P/E ratio of 87.1. In comparison, the average P/E ratio for the Health Care sector is 26.07. Furthermore, Repligen is likely overvalued compared to the book value of its equity, since its P/B ratio of 4.51 is higher than the sector average of 3.53.
Repligen Has an Average Rating of Buy:
The 14 analysts following Repligen have set target prices ranging from $160.0 to $225.0 per share, for an average of $192.14 with a buy rating. The company is trading -15.6% away from its average target price, indicating that there is an analyst consensus of some upside potential.
Repligen has an average amount of shares sold short because 6.9% of the company's shares are sold short. Institutions own 103.6% of the company's shares, and the insider ownership rate stands at 6.03%, suggesting a decent amount of insider shareholders. The largest shareholder is Price (T.Rowe) Associates Inc, whose 13% stake in the company is worth $1,157,253,864.
